MGMT-Methylated Glioblastoma
Oncology·MeSH: Glioblastoma
Prevalence
3.2 / 100K
Incidence
3.2 / 100K/yr
3 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Frequently asked questions
How many drugs are in development for MGMT-Methylated Glioblastoma?
BioSniper tracks 3 drugs in development for MGMT-Methylated Glioblastoma across 3 companies.
How many clinical trials target MGMT-Methylated Glioblastoma?
There are 2 clinical trials targeting MGMT-Methylated Glioblastoma tracked by BioSniper.
What is the prevalence of MGMT-Methylated Glioblastoma?
The estimated prevalence of MGMT-Methylated Glioblastoma is approximately 3.2 per 100,000 population.
Deep-dive into MGMT-Methylated Glioblastoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis